Not all existing therapies for type 2 diabetes provide similar glycemic control for every affected patient; with a few notable exceptions, how different responses to therapy relate to specific variations within identifiable subgroups of patients remained, and remains, largely unexplored.

Also on the basis of current uncertainty, the *Diabetes Care* Editors' Expert Forum delivered their reflections to help physicians personalize diabetes care ([@B1]). Apart from the many given reasons for the need to decode the joint position statement by the American Diabetes Association and the European Association for the Study of Diabetes (EASD) ([@B2]), the list could also include recognition of the difficulty of implementing effective personalized therapy in a clinical setting, the need to enlarge consensus, and the panoply of diabetes drugs, which may also imply the "personalization of a niche" for each different antihyperglycemic agent within the 12 drug classes on the U.S. market. However, multiple treatment guidelines, algorithms, and goals periodically released to improve guidance may also enhance uncertainty ([@B3]).

Personalized medicine should be based on evidence rather than clinical impression; unfortunately, it still lacks scientific evidence. For example, personalization of HbA~1c~ target for diabetic individuals is paramount as the aggressiveness of any therapy is ultimately based on how low the target is set. A good example of this challenge is the recent INTERVAL trial, which aims to assess the feasibility of setting and achieving individualized targets in elderly (aged 70 years or older) type 2 diabetic patients ([@B4]). Although investigators from seven European countries were free to set individualized treatment targets on the basis of age, baseline HbA~1c~, comorbidities, and frailty status, the mean investigator-defined individualized HbA~1c~ targets were around 7.0%, substantially lower than expected for that elderly population. To our knowledge, this is the only controlled study trying to apply the philosophy of personalized medicine in type 2 diabetes.

Human beings tend to revert to the familiar: given the paucity of pragmatic aid (for example, Web-driven algorithms that estimate the target with simple parameters or tailor pharmacological therapy on the basis of clinical features \[[@B5]\]), personal decisions tend to be conservative and uniform to what is familiar and known. A lesson learned is that physicians need practical help to feel safer with consistent recommendations.
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